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Case Report
A 44-year-old man with a history of
hepatitis C infection and regular use of cocaine
was asymptomatic until June 6, 1995, when he
noted the acute onset of myalgia, headache,
arthralgia, fever (40°C), nonproductive cough,
nausea, and vomiting. The following day he
sought medical care and received oral
trimethoprim/sulfamethoxazole for a presumed
respiratory tract infection. Over the next 3 days,
his symptoms worsened; on the fourth day he
noticed a maculopapular rash and came to our
medical center. Initial examination showed
tachycardia (pulse 125 beats per minute), fever
(38.6°C), and a macular red rash localized to his
right arm. The patient reported a tick bite 1 day
before his symptoms began. In addition, he
reported removing an engorged tick from his pet
dog and crushing it between his fingers 4 days
before he became ill. Laboratory studies showed
leukopenia (white blood cell count 2,700/mm3),
thrombocytopenia (platelet count 69,000/mm3),
hyponatremia (serum sodium 130 meq/dL), and
mildly elevated serum concentrations of hepatic
enzymes (serum aspartate aminotransferase
level of 160 IU/L [normal range 10 to 60 IU]). A
screening test for HIV infection was negative.
Therapy with intravenous doxycycline was begun
(100 mg twice daily). A skin biopsy showed a
perivascular lymphocytic infiltrate in the super-
ficial and deep dermis. Direct immunofluorescent
antibody staining of the fresh frozen skin biopsy
with antiserum against Rickettsia rickettsii
demonstrated organisms typical of spotted fever
group rickettsiae within endothelial cells.
Sections were also stained with antiserum
against human albumen as a negative control.
Parallel staining of a section of positive control
tissue was also performed (3). Three days after
admission, the patient was afebrile and asymp-
tomatic. He was discharged and instructed to
continue therapy with oral doxycycline for an
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additional 7 days. At follow-up 12 weeks later, he
felt well. His white blood count was 7,600/mm3,
and his platelet count was 166,000/mm3.
Serologic Tests
Serum samples obtained 5, 24, and 55 days
after onset of illness were tested for antibodies
to Ehrlichia chaffeensis and R. rickettsii antigens
by immunofluorescence assay (IFA) except that
E.  chaffeensis  (Arkansas strain) was used
instead of E. canis (4,5).
A fourfold IFA antibody rise (1:32 to 1:128)
occurred against E. chaffeensis antigen, but
antibodies against R. rickettsii antigen were not
detected in either the acute- or first convalescent-
phase serum sample. However, a serum sample
collected 55 days after onset contained an
antibody titer of 1:40 to R. rickettsii antigen.
Significant in vitro T-cell proliferation was seen
in response to the antigens of both E. chaffeensis
and R. rickettsii (Table 1).
Cell Culture Isolation and In Vitro
Lymphocyte Stimulation
A sample of blood taken before the patient
was treated with doxycycline was centrifuged in
two steps to remove red blood cells and to pellet
buffy coat cells. A portion of cellular material was
then resuspended in plasma and injected into
Vero cells and 030 cells (North Carolina State
University  canine monocytoid cell line). Vero cell
cultures were then maintained with medium 199
and 030 cells with RPMI 1640 containing 10%
fetal bovine serum, 2 mM L-glutamine, and
0.075% sodium bicarbonate. Cultures were
examined weekly for rickettsia-like organisms (5)
or morulaelike structures (6) by light microscopy.
Cell suspensions were stained by Gimenez,
Wright, and direct immunofluorescent antibody
(DFA) for R. rickettsii (rabbit anti-R. rickettsii,
Centers for Disease Control and Prevention
[CDC], Atlanta, GA) and E. chaffeensis (rabbit anti-
ehrlichia fluorescein isothiocyanate-labeled conju-
gates, J.E. Dawson, CDC, Atlanta, GA) (6,7).
Approximately 12 weeks after onset of
illness, venous blood was obtained and placed in
tubes with EDTA anticoagulant. The specimen
was shipped overnight on wet ice and then
processed as follows. An equal volume of medium
was added to a 10-ml aliquot of the blood sample,
loaded onto 6 ml of Ficoll-paque (Pharmacia,
Uppsala, Sweden), and centrifuged at 770 x g for
20 min at room temperature. The upper layer of
plasma was removed. Then the interface
(containing most of the lymphocytes) and the
Ficoll-paque (containing most of the monocytes)
were harvested and washed once with medium.
The pellet was suspended in medium (Dulbecco
modified Eagle medium [DMEM]) containing
10% fetal bovine serum, 2 mM glutamine, 5 x
10-5 M 2-mercaptoethanol, 10 µM HEPES buffer,
and 50 µg/ml of gentamicin. The concentration of
cells was adjusted to 1 x 106/ml in DMEM. A 0.1-
ml portion of these cells was then aliquoted into
each well of a 96-well plate. Serial dilutions of
inactivated intact rickettsial or ehrlichial antigen
(0.2µg to 4 µg/well) were added to individual wells
in the same plate in triplicate. The plate was then
incubated at 37°C in a 5% CO2 atmosphere for 6
days. Afterwards, 3H-thymidine was added to
each well (1 microcurie/well), and the plates were
again incubated at 37°C overnight. On the next
day the cells were harvested and dried; ß-fluor
cocktail scintillation fluid was then added, and
the mixture was counted in a ß-counter. Count
per minute rates greater than threefold of the
unstimulated control were considered positive.
After 8 days of incubation in Vero cells, a
spotted fever group rickettsia was detected by
direct immunofluorescent antibody from a sample
of blood obtained immediately before doxycycline
therapy. However, the rickettsial organism did
not thrive with subsequent in vitro passage, and
further attempts to recover the organism in vitro
or by injecting into guinea pigs were unsuccess-
ful. Subsequent attempts to amplify rickettsial
17kDa protein gene and the 16SrRNA gene by PCR
with stored cell culture materials from passages 1
and 2 were negative. In addition, morulae
consistent with ehrlichial organisms were detected
by light and direct fluorescence in blood taken
from the patient before antimicrobial therapy.
Table 1. Patient’s T-lymphocyte proliferation when
stimulated with antigens of Rickettsia rickettsii or
Ehrlichia chaffeensis
Mitogenic Quantity of Stimulation
 stimulus antigen (µg) index
R. rickettsii 2.0   17.9
1.0   26.7
0.2   14.8
E. chaffeensis 4.0   65.3
2.0   19.1
0.4   48.7
Phytohemagglutinin 5.0 271.2
1.0     8.2313 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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Subsequent attempts to isolate ehrlichiae with
further passage in 030 cells were unsuccessful.
Polymerase Chain Reaction (PCR)
Amplification/Sequencing
DNA was extracted from acute-phase blood
with a commercially available kit (IsoQuick; Orca
Research Inc., Bothell, WA) for preparation of
DNA from whole blood, according to
manufacturer’s instructions. The dried pellet was
then resuspended in DNAase-free water in
preparation for PCR analysis.
A pair of primers that recognize sequences of
the nadA gene of E. chaffeensis was used to analyze
the patient’s sample (Table 2). The PCR products
were then separated by electrophoresis in a 1%
agarose gel, stained with ethidium bromide, and
visualized under UV light (Figure A).
The amplification conditions for the 120 kDA
protein gene were essentially the same as the ones
used for the nadA gene, except that nested PCR was
performed (9-10). The outside primers were pXCF3
and pXAR4, and the nested primers were pXCF3b
and pXAR5 (Table 2). The nested primers obtained
a product similar to the 1.1 kb product amplified
from the Arkansas strain and one repeat unit larger
than the Sapulpa strain (Figure B).
Nested PCR amplification of the 120 kDa
protein gene of E. chaffeensis yielded a PCR
product from the patient’s blood similar to the
repeat region of the E. chaffeensis Arkansas
strain. The nadA gene of E. chaffeensis was
amplified by a single pair of primers; the
sequence of the nadA segment was determined to
be similar in size to that of E. chaffeensis (Figure).
Case Findings
This patient had clinical features of infection
with both R. rickettsii and E. chaffeensis. His
rash, although limited and purely macular, was
compatible with R. rickettsii infection (11).
Compelling data support the conclusion that the
patient was infected with a spotted fever group
rickettsia: 1) IFA staining of a skin specimen
showed organisms typical of spotted fever group
rickettsia, 2) a spotted fever group rickettsia was
initially recovered in tissue culture from a blood
sample taken before therapy, and 3) T-cell
lymphocytes harvested from a convalescent-phase
blood sample contained specific memory cells
reactive to R. rickettsii from which a T-lymphocyte
cell line was subsequently established.
We do not know why a typical vigorous
convalescent-antibody response to R. rickettsii
did not develop in this patient, even though
antibody response to E. chaffeensis was typical. It
is possible, but highly unlikely, that the spotted
fever group rickettsia isolated from the patient
was a species other than R. rickettsii. We cannot
state with certainty that the isolate detected in
vitro in Vero cells and then lost in subsequent
passage was indeed R. rickettsii and not a closely
related species such as R. amblyommii (12). It is
also possible that coinfection with E. chaffeensis
suppressed a normal antibody response to R.
rickettsii  antigens. Alternately, if infection
with  E. chaffeensis was transmitted by a tick bite
several days before the second bite by a tick
infected with a spotted fever group rickettsia,
antimicrobial therapy may have blunted a typical
antibody response to rickettsial—but not to
previously present ehrlichial—antigens (early
antimicrobial therapy can impair or blunt the
antibody response in patients with R. rickettsii
infection [13]). In addition, a previous report
described a patient with documented rickettsemia
who was treated within 12 hours of onset of
symptoms and failed to develop a convalescent-
phase antibody response (14).
Had we not performed a skin biopsy or
attempted to isolate rickettsiae from the blood,
we might have logically (but erroneously)
concluded that the illness was due solely to
E. chaffeensis infection.
Concurrent infection with E. chaffeensis is
supported by three different lines of evidence: 1) a
Table 2. Sequences of primers used in amplification of the NadA gene and the 120 kDa protein gene of Ehrlichia
chaffeensis
Gene Primers Sequence
NadA gene ECHNADA1 5' TCATTTCGTGCTTTCTTATTG 3'
pXCR6 5' TGCCCACATATGCGTTTG 3'
120 kDa protein gene pXCF3 5' CAGAATTGATTGTGGAGTTGG 3'
pXAR4 5' ACATAACATTCCACTTTCAAA 3'
120 kDa protein gene nested pXCF3b 5' CAGCAACAGCAAGAAGATGAC 3'
pXAR5 5' ATCTTTCTCTACAACAACCGG 3'314 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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greater than fourfold rise in IFA titer against
E. chaffeensis antigens, 2) in vitro stimulation of
T cells harvested from a convalescent-phase
blood sample with the antigen of E. chaffeensis
causing a strong lymphoproliferative response,
and 3) PCR products similar in size to the repeat
Figure. Polymerase chain reaction (PCR) products. A. With primers for the NadA  gene. Lane 1:  Patient’s sample
with an approximately 1.02-kb product; Lane 2: Negative control; Lane 3: Positive control. Ehrlichia chaffeensis
(Arkansas strain)–infected DH82 cells; Lane 4:  Molecular size markers:  fX174 phage DNA cleaved with HaeIII.
B. With nested primers for the 120 kDa protein gene. Lane 1: Patient’s sample with an approximately 1.1-kb
product; Lane 2: Positive control. E. chaffeensis (Sapulpa strain)–DH82 infected cells; Lane 3: Positive control. E.
chaffeensis (Arkansas strain)–infected DH82 cells; Lane 4: Molecular size markers:  fX174 phage DNA cleaved
with HaeIII.
Amplification conditions. Ten microliters of the patient’s DNA was added to a 90 -µl PCR reaction tube
containing 10  µl  of 10X PCR buffer (Boehringer Mannheim, Indianapolis, IN), 1 µl of PCR primers ECHNADA1
and pXCR6, final concentration 1 µM each; 2 µl deoxynucleotide triphosphates (final concentration, 200  µM); and
1 µl of Taq polymerase (Boehringer Mannheim, Indianapolis, IN). Water was added to bring the volume to 100
µl. The mixture was placed in a Progene FPROGO2Y thermocycler (Techne, Princeton, NJ). A DNA lysate
prepared from E. chaffeensis-infected DH82 cells was used as a positive control. The cycling program consisted
of 3 min at 94°C followed by 30 cycles, each of 30 sec at 94°C, 1 min at 55°C, and 2 min at 72°C, and an additional
cycle with an extension step of 3 min at 72°C.
To confirm the identity of the PCR product, we sequenced the 590 bp of the nadA gene product. After
amplification, the PCR products were purified by QIAquick, a PCR purification kit (QIAgen, Santa Clarita, CA).
The nucleotide sequence was then determined by the dideoxynucleotide method of cycle sequencing with Taq
polymerase (ABI Prism 377 DNA sequencer, Perkin-Elmer Corp., Foster City, CA). The sequencing reaction was
carried out for each strand of DNA. The sequencing data were analyzed by Genetics Computer Group, Wisconsin
Package software; 99.8% identity of the 590-bp overlap with nadA nucleotide sequence of Arkansas strain (Gen
Bank accession number U90900) was obtained (8).
A
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region of the 120 kDA surface protein gene of E.
chaffeensis Arkansas strain and specific for the
E. chaffeensis nadA gene recovered from a
sample of blood obtained before therapy.
Although we did not sequence amplicon
generated from the 120 kDa protein gene, the
oligonucleotide primers that were used in PCR
amplification are derived from regions of the 120
kDa protein gene that are unique to E. chaffeensis.
These regions are not present in other bacteria,
including closely related Ehrlichia species.
We are unable to determine if the patient was
infected by two different ticks or one tick
simultaneously infected with E. chaffeensis and
R. rickettsii or another spotted fever group
rickettsia. Coinfection of Ixodes scapularis ticks
with the agent of human granulocytic ehrlichiosis
or a closely related organism and B. burgdorferi
has been described (15-17); however, to our
knowledge, simultaneous infection of a tick with
R. rickettsii and E. chaffeensis has not.
Furthermore, the major vector of E. chaffeensis in
North Carolina is thought to be Amblyomma
americanum (18), and the primary vector for R.
rickettsii in this area is Dermacentor variabilis.
Although E. chaffeensis has been detected on one
occasion in D. variabilis (19), the evidence that A.
americanum is a vector for Rocky Mountain
spotted fever elsewhere is circumstantial; to our
knowledge, R. rickettsii has never been isolated
from A. americanum (W. Burgdorfer, pers. comm.).
Most likely E. chaffeensis was transmitted to
the patient from A. americanum, and the spotted
fever rickettsia was transmitted from D. variabilis.
Indeed, a walk in the fields of the Piedmont
region of North Carolina in the spring
frequently results in attachment of numerous
ticks of both species. Since the patient had
direct contact or bites with two different ticks
before his illness, we suspect that he was
infected by separate ticks rather than by one
tick infected with both pathogens.
Finally, this case is remarkable in an
additional way. Despite coinfection with two
pathogens, the patient had a relatively mild
illness. He did not have shock, major organ
dysfunction, or central nervous system involve-
ment; and with doxycycline therapy, recovery
was prompt and uneventful.
On the basis of this case report, we cannot
predict that future cases will have a benign
course or an impaired or absent convalescent-
phase antibody response to one or more of the
infecting agents. However, the patient’s illness
illustrates that coinfection with a spotted fever
group rickettsia and E. chaffeensis may occur in
areas where both diseases are endemic. The
frequency of human coinfection with ehrlichial
and rickettsial agents is unknown. Serologic
studies have demonstrated that approximately one
third of patients with antibodies to E. chaffeensis
also have antibodies to one or more rickettsiae (20).
Whether this phenomenon is due to the presence of
cross-reactive antigens or actual immune stimula-
tion by simultaneous or sequential multiple tick-
borne pathogens is unknown.
Dr. Sexton is a professor in the Department of
Medicine, Division of Infectious Diseases, Duke
University Medical Center, Durham, North Carolina.
His research interests include the clinical and
epidemiologic features of Rocky Mountain spotted
fever and other tick-borne diseases.
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